Th1/Th2 Cytokine Profiles and Their Relationship to Clinical Features in Patients Following Nonmyeloablative Allogeneic Stem Cell Transplantation

American Journal of Hematology

Volumn 75, Issue 2, 2004, Pages 78-83

  Guo, Hongfeng ^a   Qiao, Zhenhua ^a   Zhu, Lei ^a   Wang, Hongwei ^a   Su, Liping ^a   Lu, Yujin ^a   Cui, Yuee ^a   Jiang, Bo ^a   Zhu, Qioujuan ^a   Xu, Lianrong ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; Interferon ; Type 1 T cells

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUSULFAN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; CYTOMEGALOVIRUS ANTIBODY; FLUCONAZOLE; FLUDARABINE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYTOKINES; FEMALE; HUMANS; LEUKEMIA; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; TH1 CELLS; TH2 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 10744232881     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10443     Document Type: Article

References (26)

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
2. Del Prete G, Maggi E, Romagnani S. Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. Lab Invest 1994;70:299-306.
3. Yamamura M. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1992;255:12.
4. Ferrara JL. The cytokine modulation of acute graft-versus-host disease. Bone Marrow Transplant 1998;21:S13-15.
5. Biron CA. Cytokines in the generation of immune responses to, and resolution of, virus infection. Curr Opin Immunol 1994;6: 530-538.
6. Moine AL, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002;73:1373-1381.
7. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-2759.
8. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma 2000;38:221γ234.
9. Blazar BR, Korngold R, Vallera DA. Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997;157: 79-109.
10. Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 2000;105:1289-1298.
11. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
12. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L. The graft-versus-leukemia (GVL) phenomenon. Is GVL separable from GVHD? Bone Marrow Transplant 1990;6:155-161.
13. Barrett AJ. Non-myeloablative stem cell transplants. Br J Hematol 2000;111:6-17.
14. Glucksberg H, Storb R, Fefer A, Bucker CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors. Transplantation 1974;18:295-304.
15. Anderson SJ, Coleclough C. Regulation of CD4 and CD8 expression on mouse T cells. Active removal from the surface by two mechanisms. J Immunol 1993;151:5123-5134.
16. Korngold R, Sprent J. T-cell subset and graft-versus-host disease. Transplantation 1987;44:335-339.
17. Hamilton BL, Parkman R. Kinetics of the anti-recipient cytotoxic cell response of mice with minor histocompatibility antigen graft-vs-host disease. J Immunol 1982;128:376-379.
18. Krenger W, Hill GR, Ferrara JM. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997;64:553-558.
19. Dickinson AM, Sviland L, Dunn J, Carey P, Proctor SJ. Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explants models. Bone Marrow Transplant 1991;7:209-216.
20. Mowat A. Antibodies to IFN-γ prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989;68:18-23.
21. Mason DW, Dallman M, Barclay AN. Graft-versus-host disease induces expression of la antigen in rat epidermal cells and gut epithelium. Nature 1981;293:150-151.
22. Huber C, Niederwieser D. Role of cytokines and major histocompatibility complex antigens in graft-versus-host disease: in vitro studies using T cell lines and keratinocytes or hemopoietic targets. Haematol Blood Transfus 1990;33:652-654.
23. Wall DA, Sheehan KC. The role of tumor necrosis factor-α and interferon-γ in graft-versus-host disease and related immunodeficiency. Transplantation 1994;57:273-279.
24. Holda JH, Maier T, Claman NH, Evidence that IFN-γ is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 1988;45:772-777.
25. +, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 1996;2:118-125.
26. Lee PP, Zeng D, McCauly AE, Chen YF, Geiler C, Umetsu DT, Chao NJ. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 1997;90:1611-1617.